Increased SARS-CoV-2-related hospitalization and mortality in rheumatoid arthritis patients receiving rituximab therapy-a monocentric retrospective study

Please use this identifier to cite or link to this item: http://localhost:8080/xmlui/handle/123456789/12179

Full metadata record

DC Field	Value	Language
dc.contributor.author	Wang, Chrong-Reen	-
dc.contributor.author	Hsu, Chih-Hui	-
dc.contributor.author	Lin, Wei-Chieh	-
dc.date.accessioned	2025-07-18T02:51:33Z	-
dc.date.available	2025-07-18T02:51:33Z	-
dc.date.issued	2025-01	-
dc.identifier.uri	http://localhost:8080/xmlui/handle/123456789/12179	-
dc.description.abstract	From 2022 April to 2024 August, retrospective analyses by multivariable logistic regression were conducted in 341 rheumatoid arthritis patients receiving rituximab (RTX), tofacitinib (TOF) or disease-modifying-antirheumatic drug (DMARD) alone therapy. Compared to DMARD alone or TOF treatment, RTX therapy had increased adjusted odds ratios of SARS-CoV-2-related hospitalization, pneumonia and mortality	en_US
dc.language.iso	en_US	en_US
dc.publisher	Elsevier Taiwan LLC	en_US
dc.subject	SARS-CoV-2	en_US
dc.subject	Rheumatoid arthritis	en_US
dc.subject	Rituximab	en_US
dc.subject	Hospitalization	en_US
dc.subject	COVID19 pneumonia	en_US
dc.subject	Mortality	en_US
dc.title	Increased SARS-CoV-2-related hospitalization and mortality in rheumatoid arthritis patients receiving rituximab therapy-a monocentric retrospective study	en_US
dc.type	Article	en_US
Appears in Collections:	Vol 58 No 2 (2025)

Files in This Item:

File	Description	Size	Format
Increased-SARS-CoV-2-related-hospitalization-and-morta_2025_Journal-of-Micro.pdf		924.05 kB	Adobe PDF	View/Open

DSpace JSPUI